Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma.

58 The only thromboprophylaxis trial in glioma patients, the PRODIGE trial (randomization between dalteparin 5000 IU OD [ n = 99] and placebo [ n = 87]), showed a trend toward decreased VTE (9.1% vs. 15% in 6 months, respectively) but increased ICH incidence (5.1% vs. 1.2%), although it had low statistical power (aimed sample size was 217 patients per group) because of slow accrual. 59 The Cassini trial, evaluating rivaroxaban, had primary brain cancer as an e

also in 53,322 other papers